Premium
Infliximab
Author(s) -
Winterfield Laura S.,
Menter Alan
Publication year - 2004
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1396-0296.2004.04044.x
Subject(s) - infliximab , medicine , psoriatic arthritis , psoriasis , tumor necrosis factor alpha , monoclonal antibody , immunology , dermatology , tumor necrosis factor α , arthritis , disease , antibody
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro‐inflammatory cytokine tumor necrosis factor‐alpha (TNF‐α). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF‐α in the immunopathogenesis of psoriatic disease. This review summarizes the current data regarding the use of infliximab in treating psoriasis and psoriatic arthritis, as well as the safety data available from patients with other immune‐mediated inflammatory disorders. Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed.